Company intelligence / Profile preview

Eiger Capital

Palo Alto, California, United Stateseigercapital.com ↗

Ownership: Private
Development stage: Other

Overview

Eiger BioPharmaceuticals developed therapies for rare and ultra-rare diseases. Its only commercial product was Zokinvy for progeria. Avexitide reached Phase 2/Phase 3 readiness with FDA Breakthrough designation before being sold to Amylyx Pharmaceuticals. Lonafarnib was developed through late-stage clinical trials for hepatitis delta virus infection before being sold to Eiger InnoTherapeutics. The company filed for Chapter 11 bankruptcy in April 2024 and subsequently liquidated its assets.

Therapeutic areas: Rare DiseasesEndocrinologyInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Eiger Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eiger Capital.

Explore the full profile